c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L promotes apoptosis in cancer cells while sparing normal cells. Although many cancers are sensitive to TRAIL-induced apoptosis, some evade the proapoptotic effects of TRAIL. Therefore, differentiating molecular mechanisms that distinguish between TRAIL-sensitive and TRAIL-resistant tumors are essential for effective cancer therapies. Here, we show that c-Fos functions as a proapoptotic agent by repressing the antiapoptotic molecule c-FLIP(L). c-Fos binds the c-FLIP(L) promoter, represses its transcriptional activity, and reduces c-FLIP(L) mRNA and protein levels. Therefore, c-Fos is a key regulator of c-FLIP(L), and activation of c-Fos determines whether a cancer cell will undergo cell death after TRAIL treatment. Strategies to activate c-Fos or inhibit c-FLIP(L) may potentiate TRAIL-based proapoptotic therapies.

[1]  Xiaoping Zhang,et al.  Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. , 2007, Cancer letters.

[2]  Xiaoping Zhang,et al.  MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). , 2007, Cancer research.

[3]  L. Shemshedini,et al.  c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation , 1998, Endocrine.

[4]  E. Wagner,et al.  Fos/AP‐1 proteins in bone and the immune system , 2005, Immunological reviews.

[5]  W. Gerald,et al.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. , 2005, Molecular endocrinology.

[6]  S. Shirasawa,et al.  Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway* , 2005, Journal of Biological Chemistry.

[7]  Jeffrey P. MacKeigan,et al.  Graded Mitogen-Activated Protein Kinase Activity Precedes Switch-Like c-Fos Induction in Mammalian Cells , 2005, Molecular and Cellular Biology.

[8]  D. Hochbaum,et al.  Phosphorylation of c-Fos by Members of the p38 MAPK Family , 2005, Journal of Biological Chemistry.

[9]  P. Krammer,et al.  c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[10]  B. Bonavida,et al.  Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention , 2005, Oncogene.

[11]  J. Voorhees,et al.  Ultraviolet Irradiation Induces Smad7 via Induction of Transcription Factor AP-1 in Human Skin Fibroblasts* , 2005, Journal of Biological Chemistry.

[12]  E. Wagner,et al.  Essential role of RSK2 in c-Fos-dependent osteosarcoma development. , 2005, The Journal of clinical investigation.

[13]  W. El-Deiry,et al.  Overview of cell death signaling pathways , 2005, Cancer biology & therapy.

[14]  W. El-Deiry,et al.  Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity , 2004, Molecular and Cellular Biology.

[15]  Hongmei Yang,et al.  Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate Cancer , 2004, Cancer Research.

[16]  A. Ashkenazi,et al.  Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.

[17]  Emelyn H. Shroff,et al.  Nuclear Factor of Activated T Cells Balances Angiogenesis Activation and Inhibition , 2004, The Journal of experimental medicine.

[18]  H. Stein,et al.  c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor–induced Apoptosis , 2004, The Journal of experimental medicine.

[19]  B. Pulendran,et al.  Cutting Edge: Different Toll-Like Receptor Agonists Instruct Dendritic Cells to Induce Distinct Th Responses via Differential Modulation of Extracellular Signal-Regulated Kinase-Mitogen-Activated Protein Kinase and c-Fos 1 , 2003, The Journal of Immunology.

[20]  M. Hatano,et al.  Dominant-negative effect of the c-fos family gene products on inducible NO synthase expression in macrophages. , 2003, International immunology.

[21]  Charles H. Lin,et al.  Interferon Regulatory Factor-7 Synergizes with Other Transcription Factors through Multiple Interactions with p300/CBP Coactivators* , 2003, The Journal of Biological Chemistry.

[22]  J. Tschopp,et al.  The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex* , 2002, The Journal of Biological Chemistry.

[23]  C. Acquaviva,et al.  Multiple Degradation Pathways for Fos Family Proteins , 2002, Annals of the New York Academy of Sciences.

[24]  Xiaolu Yang,et al.  c‐FLIPL is a dual function regulator for caspase‐8 activation and CD95‐mediated apoptosis , 2002, The EMBO journal.

[25]  M. Olive,et al.  Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines , 2002, Cancer Gene Therapy.

[26]  J. Blenis,et al.  Fas-associated Death Domain Protein (FADD) and Caspase-8 Mediate Up-regulation of c-Fos by Fas Ligand and Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) via a FLICE Inhibitory Protein (FLIP)-regulated Pathway* , 2001, The Journal of Biological Chemistry.

[27]  J. Tschopp,et al.  NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.

[28]  Peter Scheurich,et al.  NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.

[29]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[30]  Niels Grabe,et al.  AliBaba2: Context specific identification of transcription factor binding sites , 2000, Silico Biol..

[31]  Lars E. French,et al.  The TRAIL to selective tumor death , 1999, Nature Medicine.

[32]  T. Herdegen,et al.  Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins , 1998, Brain Research Reviews.

[33]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[34]  B. Lim,et al.  Activation of the c-fos serum response element by phosphatidyl inositol 3-kinase and rho pathways in HeLa cells. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[35]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[36]  J. Barrett,et al.  Induction of apoptosis by c-Fos protein , 1996, Molecular and cellular biology.

[37]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[38]  M. Karin,et al.  c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK , 1994, Nature.

[39]  Eithne Costello,et al.  Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. , 1994, Oncogene.

[40]  Richard J Smeyne,et al.  Continuous c-fos expression precedes programmed cell death in vivo , 1993, Nature.

[41]  D. Donner,et al.  Tumour necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. , 1993, The Biochemical journal.

[42]  J. Manak,et al.  Casein kinase II enhances the DNA binding activity of serum response factor. , 1990, Genes & development.

[43]  F. C. Lucibello,et al.  Trans-repression of the mouse c-fos promoter: A novel mechanism of fos-mediated trans-regulation , 1989, Cell.

[44]  I. Verma,et al.  Transcriptional autoregulation of the proto-oncogene fos , 1988, Nature.